Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Agios Pharmaceuticals, Inc.

AGIO · Nasdaq · USD · Market cap $1.8B · 539 employees

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

FAIL · Does not pass the screen
27.60 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price27.60 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 2.13)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $32.00 to $59.36, base estimate $43.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders insiders sold, $296,470, latest filing 2026-10-26
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 2.13, read 2026-11-19
  • Ethical does not pass the values gate
Price27.60 USD
Fair value43.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-12Read Markup32.82-15.9% to today Distribution gives way to Markup first Markup read since November
2026-11-05Read Distribution31.38-12.0% to today ✓Markup gives way to Distribution after a 16% slide in 10 days
2026-10-26Read Markup37.18-25.8% to today Markdown gives way to Markup after a 13% rise in 5 weeks
2026-09-21Read Markdown32.95-16.2% to today ✓Distribution gives way to Markdown with volume flow in agreement

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Agios Pharmaceuticals, Inc. holds its Markup at $27.60. The statistical read favours the sellers, held for 10 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 10 days
Price at the screen$27.60
ValuationN/A trailing · -9.36 forward price to earnings
Values screenFAIL · score 70.0
Beta0.62
The Workings

Five Screens: AGIO's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 3.10% Below 33% Pass
Interest-bearing cash 23.90% Below 33% Pass
Receivables 7.69% Below 49% Pass
Revenue purity 100.00% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Agios Pharmaceuticals, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when AGIO's ethical verdict changes

Today AGIO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 36% discount to our $43.00 fair value, 330.00% revenue growth.

Method.

32.00Conservative43.00Base case59.36Growth case 27.60Price

USD, 2026-11-20 screen. A 35.8% under base.

The Street's Range
32.00Street low 43.00Street average 74.00Street high 27.60Price

Street: 9 covering, consensus Buy. Average target +56%.

Chart
The Business, in Plain Words

New Enzyme Drug Drives Biotech Revenue Explosion

Picture a patient finally getting a pill that switches a faulty enzyme back on in rare blood disorders. Agios has just launched that product and revenue has leapt 138 percent, yet we pass. A negative forward earnings multiple and zero profit margins show this is still early revenue from one asset, not a durable business with proven economics.

The ethical screen raises no issues. Unknown competitive protection and a negative 33 percent return on equity leave it vulnerable once larger firms target the same cellular metabolism space.

Risks centre on clinical setbacks, ongoing cash burn and dilution before any sustained profits appear. The modest gap to fair value does not offset the binary nature of drug development. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-9.4x
EPS, trailing-6.31
EPS, forward-3.19
Revenue growth+330.0%growing very fast
Profit margin-264.8%currently unprofitable
Return on equity-32.9%not currently earning a positive return on equity
FCF yield-14.79%
Debt to equity2.71heavy leverage: higher risk if revenue softens
Current ratio9.69comfortably covers its short-term bills
Beta0.62steadier than the market
Short interest, float0.11%
52-week range22.24 - 46.00
Market cap$1.8B
Employees539

AGIO-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $29.68 +0.0% Entry 22
2026-11-19 Markup $29.68 -9.6% Entry 21
2026-11-12 Markup · changed $32.82 +4.6% Entry 20

The framework has shifted from distribution to markup since the last review.

2026-11-05 Distribution · changed $31.38 +0.6% Entry 19

The framework has shifted from markup to distribution since the last review.

2026-11-04 Markup $31.20 +2.1% Entry 18
2026-11-03 Markup $30.55 +0.0% Entry 17
2026-11-02 Markup $30.55 +0.0% Entry 16
2026-11-01 Markup $30.55 -19.7% Entry 15
2026-10-31 Markup $38.03 +0.0% Entry 14
2026-10-30 Markup $38.03 +0.0% Entry 13

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on AGIO

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in AGIO's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · AGIO
DateInsiderTitleTypeSharesValue
2026-10-26 Gheuens Sarah Chief Medical Officer S - Sale+OE 7,866 $296,470
2026-10-21 Gheuens Sarah Chief Medical Officer S - Sale+OE 1,989 $74,642

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming AGIO
DatePoliticianPartyTypeAmount
2026-08-20 Gil Cisneros Democrat buy 1K–15K
2026-08-20 Gil Cisneros Democrat buy 1K–15K
2026-08-20 Gil Cisneros Democrat buy 1K–15K
2026-08-20 Gil Cisneros Democrat buy 1K–15K
2026-08-20 Gil Cisneros Democrat buy 1K–15K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $27.99 +3.0% · $1,030 +3.0%
2 months $32.92 -12.5% · $876 -12.5%
3 months $27.59 +4.5% · $1,045 +4.5%
6 months $27.46 +5.0% · $1,050 +5.0%
1 year $34.51 -16.5% · $835 -16.5%
2 years $47.22 -39.0% · $610 -39.0%
3 years $25.87 +11.4% · $1,114 +11.4%
5 years $57.74 -50.1% · $499 -50.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AGIO does next, these words stay.

Agios Pharmaceuticals, Inc. · AGIO · Markup · $27.60
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.